Login

Switch On Your HIV Smarts.

NEXT-PrEP: A New Study of Maraviroc for HIV Prevention

NEXT-PrEP: A New Study of Maraviroc for HIV Prevention

, by San Francisco AIDS Foundation

Learn more about the NEXT-PrEP study—the first to test the antiretroviral drug maraviroc as a once-daily HIV-prevention pill. Read More

FDA Approves Truvada for PrEP

FDA Approves Truvada for PrEP

, by Reilly O'Neal

See why this new HIV prevention tool is both essential and controversial—and why there's still work to do around PrEP. Read More

AIDS 2012: D.C. Declaration Maps Route to Ending AIDS

AIDS 2012: D.C. Declaration Maps Route to Ending AIDS

, by Reilly O'Neal

“The goal of beginning to end the AIDS epidemic is ambitious, but achievable. It is within our grasp.” Learn about a new call to action for everyone working to end HIV/AIDS. Read More

Ask a Guinea Pig: What Do I Need to Know Before Joining a PrEP Trial?

Ask a Guinea Pig: What Do I Need to Know Before Joining a PrEP Trial?

, by Matt Sharp

BETA's new column shares an insider perspective on taking part in clinical trials. Thinking of joining a study of PrEP—a pill a day for HIV prevention? Start here. Read More

PrEP: The Road Ahead

PrEP: The Road Ahead

, by San Francisco AIDS Foundation

Studies of PrEP—in which HIV-negative individuals take antiretroviral drugs to avoid acquiring HIV—are ongoing around the world. Learn more about the road ahead for this promising (and controversial) new HIV prevention strategy. Read More